Compounds > n-ethyl-4-toluenesulfonamide
Page last updated: 2024-12-05

n-ethyl-4-toluenesulfonamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID6637
CHEMBL ID1492809
SCHEMBL ID126985
MeSH IDM0220694

Synonyms (63)

Synonym
AKOS000431178
NCIOPEN2_000527
80-39-7
p-toluenesulfonamide, n-ethyl-
n-ethyl-p-tolylsulfonamide
santicizer 3
nsc68803
n-ethyl-p-toluenesulfonamide
nsc-68803
n-tosylethylamine
p-tolueneethylsulfonamide
n-ethyl-p-methylbenzenesulfonamide
p-toluenesulfonyl-n-ethylamide
benzenesulfonamide, n-ethyl-4-methyl-
NCGC00091206-01
n-ethyl-4-methylbenzenesulfonamide
ccris 6037
nsc 68803
n-ethyl-4-toluenesulfonamide
einecs 201-275-1
n-ethyltoluene-4-sulphonamide
ethyl tosylamide
n-ethyl-p-toluenesulfonamide, 98%
n-ethyl-4-methyl benzenesulfonamide
STK416319
E0674
HMS1661F02
ohpzpbndovqjmh-uhfffaoysa-
inchi=1/c9h13no2s/c1-3-10-13(11,12)9-6-4-8(2)5-7-9/h4-7,10h,3h2,1-2h3
n-ethyl-4-methyl-benzenesulfonamide
A839926
A9951
NCGC00091206-02
tox21_200366
dtxcid405310
dtxsid5025310 ,
NCGC00257920-01
cas-80-39-7
unii-992s798sjb
992s798sjb ,
FT-0631358
ethyl p-toluenesulfonamide
p-toluene-n-ethylsulfonamide
1321-54-6
ethyl-p-toluenesulfonamide
CHEMBL1492809
n-ethyl(4-methyl phenyl) sulfonamide
SCHEMBL126985
n-ethyl-4-methylbenzene-1-sulfonamide
W-104236
cbz-d-phenylalaninemethylester
n-ethyl-p-toluene sulfonamide
unipex 108
4-toluenesulfonamide, n-ethyl-
ethyl toluenesulfonamide
Z45528338
n-ethyl-4-toluene sulfonamide
AS-14234
EN300-15862
Q27272165
CS-0151957
n-ethyl-4-methylbenzenesulfonamide 100 microg/ml in acetonitrile
n-ptsa
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
acetylcholinesteraseHomo sapiens (human)Potency73.01130.002541.796015,848.9004AID1347395
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
progesterone receptorHomo sapiens (human)Potency31.48100.000417.946075.1148AID1346795
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency70.47720.003041.611522,387.1992AID1159552
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (14.29)18.2507
2000's1 (14.29)29.6817
2010's4 (57.14)24.3611
2020's1 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.69

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.69 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.77 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.69)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (14.29%)4.05%
Observational0 (0.00%)0.25%
Other6 (85.71%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
toluene
methylbenzene : Any alkylbenzene that is benzene substituted with one or more methyl groups.		2.420methylbenzene;
toluenes;
volatile organic compound		cholinergic antagonist;
fuel additive;
neurotoxin;
non-polar solvent
aniline
[no description available]		2.0210anilines;
primary arylamine
isophorone
isophorone : A cyclic ketone, the structure of which is that of cyclohex-2-en-1-one substituted by methyl groups at positions 3, 5 and 5.		2.0210cyclic ketone;
enone		plant metabolite;
solvent
2,4-di-tert-butylphenol
2,4-di-tert-butylphenol: structure given in first source. 2,4-di-tert-butylphenol : A member of the class of phenols carrying two tert-butyl substituents at positions 2 and 4.		2.0210alkylbenzene;
phenols		antioxidant;
bacterial metabolite;
marine metabolite
tiletamine hydrochloride
Cyclohexanones: Cyclohexane ring substituted by one or more ketones in any position.. cyclohexanones : Any alicyclic ketone based on a cyclohexane skeleton and its substituted derivatives thereof.		2.0210
n,n-bis(2-hydroxyethyl)-4-toluidine
N,N-bis(2-hydroxyethyl)-4-toluidine: lysosome stabilizing agent		1.9810
ConditionIndicatedRelationship StrengthStudiesTrials
Encephalitis, Polio
[description not available]		02.0610
Poliomyelitis
An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)		02.0610
Plasmodium falciparum Malaria
[description not available]		02.110
Malaria, Falciparum
Malaria caused by PLASMODIUM FALCIPARUM. This is the severest form of malaria and is associated with the highest levels of parasites in the blood. This disease is characterized by irregularly recurring febrile paroxysms that in extreme cases occur with acute cerebral, renal, or gastrointestinal manifestations.		02.110
Anemia, Fanconi
[description not available]		02.1310
Fanconi Anemia
Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)		02.1310
Allergic Contact Dermatitis
[description not available]		01.9810
Dermatitis, Occupational
A recurrent contact dermatitis caused by substances found in the work place.		01.9810
Hand Dermatosis
[description not available]		01.9810
Hand Dermatoses
Skin diseases involving the HANDS.		01.9810
Dermatitis, Allergic Contact
A contact dermatitis due to allergic sensitization to various substances. These substances subsequently produce inflammatory reactions in the skin of those who have acquired hypersensitivity to them as a result of prior exposure.		01.9810